tiprankstipranks
Trending News
More News >
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
US Market

Kazia Therapeutics (KZIA) Stock Statistics & Valuation Metrics

Compare
290 Followers

Total Valuation

Kazia Therapeutics has a market cap or net worth of $5.35M. The enterprise value is ―.
Market Cap$5.35M
Enterprise Value

Share Statistics

Kazia Therapeutics has 1,117,859 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,117,859
Owned by Insiders
Owned by Institutions

Financial Efficiency

Kazia Therapeutics’s return on equity (ROE) is 2.67 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)2.67
Return on Assets (ROA)-1.24
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee256.44K
Profits Per Employee-2.98M
Employee Count9
Asset Turnover0.11
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Kazia Therapeutics is -0.03. Kazia Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.03
PS Ratio0.00
PB Ratio-0.04
Price to Fair Value-0.08
Price to FCF-0.49
Price to Operating Cash Flow-0.04
PEG Ratio<0.01

Income Statement

In the last 12 months, Kazia Therapeutics had revenue of 2.31M and earned -26.78M in profits. Earnings per share was -11.17.
Revenue2.31M
Gross Profit2.31M
Operating Income0.00
Pretax Income-27.05M
Net Income-26.78M
EBITDA-26.77M
Earnings Per Share (EPS)-11.17

Cash Flow

In the last 12 months, operating cash flow was -9.58M and capital expenditures 0.00, giving a free cash flow of -9.58M billion.
Operating Cash Flow-9.58M
Free Cash Flow-9.58M
Free Cash Flow per Share-8.57

Dividends & Yields

Kazia Therapeutics pays an annual dividend of $156.513, resulting in a dividend yield of ―
Dividend Per Share$156.513
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.34
52-Week Price Change-57.21%
50-Day Moving Average3.75
200-Day Moving Average12.77
Relative Strength Index (RSI)75.43
Average Volume (3m)30.96K

Important Dates

Kazia Therapeutics upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend DateJan 28, 2013

Financial Position

Kazia Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -6.33%
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.81
Net Debt to EBITDA0.04
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Kazia Therapeutics has paid -271.00K in taxes.
Income Tax-271.00K
Effective Tax Rate0.01

Enterprise Valuation

Kazia Therapeutics EV to EBITDA ratio is -0.25, with an EV/FCF ratio of -0.71.
EV to Sales2.93
EV to EBITDA-0.25
EV to Free Cash Flow-0.71
EV to Operating Cash Flow-0.71

Balance Sheet

Kazia Therapeutics has $1.66M in cash and marketable securities with AU$634.00K in debt, giving a net cash position of -$1.02M billion.
Cash & Marketable Securities$1.66M
Total DebtAU$634.00K
Net Cash-$1.02M
Net Cash Per Share-$0.92
Tangible Book Value Per Share-$10.60

Margins

Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of -1160.23%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin-1171.97%
Net Profit Margin-1160.23%
EBITDA Margin-1159.71%
EBIT Margin-1240.68%

Analyst Forecast

The average price target for Kazia Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside180.90% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast19.58%

Scores

Smart ScoreN/A
AI Score31
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis